Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Do cannabinoids reduce multiple sclerosis-related spasticity?

Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM.

Neurologist. 2009 Nov;15(6):369-71. doi: 10.1097/NRL.0b013e3181bf5572.

PMID:
19901724
2.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
3.
4.

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group.

Lancet. 2003 Nov 8;362(9395):1517-26.

PMID:
14615106
5.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
6.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
7.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
8.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group.

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
9.

Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.

Meuth SG, Vila C, Dechant KL.

Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11. Review.

PMID:
26166264
10.

Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.

Smith PF.

Curr Opin Investig Drugs. 2002 Jun;3(6):859-64. Review.

PMID:
12137404
11.

[Cannabinoids for symptomatic therapy of multiple sclerosis].

Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC.

Nervenarzt. 2012 Jun;83(6):695-704. doi: 10.1007/s00115-011-3401-9. Review. German.

PMID:
22080198
12.

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B.

CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14.

13.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Bazinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2015 May 11;177(20):956-60. Review. Danish.

PMID:
26535431
14.

Cannabinoids and multiple sclerosis.

Pertwee RG.

Pharmacol Ther. 2002 Aug;95(2):165-74. Review.

PMID:
12182963
15.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2003;(4):CD001332. Review.

PMID:
14583932
16.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Basinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2014 Mar 17;176(12A). pii: V09130552. Review. Danish.

PMID:
25350886
17.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
18.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

19.

Are cannabinoids effective in multiple sclerosis?

Meza R, Peña J, García K, Corsi O, Rada G.

Medwave. 2017 Mar 10;17(Suppl1):e6865. doi: 10.5867/medwave.2017.6865. Review. Spanish, English.

PMID:
28306712
20.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J.

JAMA. 2015 Jun 23-30;313(24):2456-73. doi: 10.1001/jama.2015.6358. Review. Erratum in: JAMA. 2016 Apr 12;315(14):1522. JAMA. 2015 Dec 1;314(21):2308. JAMA. 2015 Aug 4;314(5):520. JAMA. 2015 Aug 25;314(8):837.

PMID:
26103030

Supplemental Content

Support Center